Evidence map›Paper›PMID 24312560›Full record

ArticlePloS one2013

RhoC interacts with integrin α5β1 and enhances its trafficking in migrating pancreatic carcinoma cells.

Ningfeng Fiona Li, Emilios Gemenetzidis, Francis J Marshall, Derek Davies, Yongwei Yu, Kristopher Frese, Fieke E M Froeling, Adam K Woolf, Roger M Feakins, Yoshiki Naito and 4 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Enhanced radiotheranostic targeting of integrinActa pharmaceutica Sinica. B · 2025
    Article
  3. Article
  4. Review
  5. B cells in pancreatic cancer stroma.World journal of gastroenterology · 2022
    Review
  6. Role of RhoC in cancer cell migration.Cancer cell international · 2021
    Review
  7. Article
  8. The Roles of Integrin α5β1 in Human Cancer.OncoTargets and therapy · 2020
    Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 3 countries.

Ningfeng Fiona LiBarts Cancer Institute - a CR-United Kingdom Centre of Excellence, Queen Mary University of London, Centre for Tumour Biology, London, United Kingdom.
Emilios Gemenetzidis
Francis J Marshall
Derek Davies
Yongwei Yu
Kristopher Frese
Fieke E M Froeling
Adam K Woolf
Roger M Feakins
Yoshiki Naito
Christine Iacobuzio-Donahue
David A Tuveson
Ian R Hart
Hemant M Kocher
Queen Mary University of London · GBCancer Research UK Cambridge Center · GBJohns Hopkins Medicine · USRoyal London Hospital · GBSecond Military Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human pancreatic ductal adenocarcinoma (PDAC) is characterized by early systemic dissemination. Although RhoC has been implicated in cancer cell migration, the relevant underlying molecular mechanisms remain unknown. RhoC has been implicated in the enhancement of cancer cell migration and invasion, with actions which are distinct from RhoA (84% homology), and are possibly attributed to the divergent C-terminus domain. Here, we confirm that RhoC significantly enhances the migratory and invasive properties of pancreatic carcinoma cells. In addition, we show that RhoC over-expression decreases cancer cell adhesion and, in turn, accelerates cellular body movement and focal adhesion turnover, especially, on fibronectin-coated surfaces. Whilst RhoC over-expression did not alter integrin expression patterns, we show that it enhanced integrin α5β1 internalization and re-cycling (trafficking), an effect that was dependent specifically on the C-terminus (180-193 amino acids) of RhoC protein. We also report that RhoC and integrin α5β1 co-localize within the peri-nuclear region of pancreatic tumor cells, and by masking the CAAX motif at the C-terminal of RhoC protein, we were able to abolish this interaction in vitro and in vivo. Co-localization of integrin α5β1 and RhoC was demonstrable in invading cancer cells in 3D-organotypic cultures, and further mimicked in vivo analyses of, spontaneous human, (two distinct sources: operated patients and rapid autopsy programme) and transgenic murine (LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre), pancreatic cancers. In both cases, co-localization of integrin α5β1 and RhoC correlated with poor differentiation status and metastatic potential. We propose that RhoC facilitates tumor cell invasion and promotes subsequent metastasis, in part, by enhancing integrin α5β1 trafficking. Thus, RhoC may serve as a biomarker and a therapeutic target.

Indexed as

Cell MovementAnimalsCell AdhesionCell DifferentiationEnzyme ActivationHumansIntegrin alpha5beta1MiceNeoplasm InvasivenessNeoplasm MetastasisPancreatic NeoplasmsProtein BindingProtein TransportrhoC GTP-Binding Proteinrho GTP-Binding ProteinsSignal TransductionIntegrin alpha5beta1rhoC GTP-Binding ProteinRHOC protein, humanrho GTP-Binding Proteinssrc-Family Kinases

Identifiers

PMID24312560
PMCPMC3849283
OpenAlexW2044913143

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.